Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Novartis Pharmaceuticals Corp
WARNING LETTER
•Novartis Pharmaceuticals Corp•September 25, 2008

Novartis Pharmaceuticals Corp – FDA Warning Letter, Sep 25, 2008

Record Details

The FDA's Division of Drug Marketing, Advertising, and Communications (DDMAC) issued a Warning Letter to Novartis Pharmaceuticals Corporation regarding promotional materials for Focalin XR (dexmethylphenidate hydrochloride) extended-release capsules CII. The review of a professional slide deck (FCL-MD-0057-A) and a webpage for Focalin XR found them to be false or misleading, overstating efficacy and broadening the drug's indication, thus misbranding the drug in violation of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 352(a) & (n)) and FDA regulations (21 CFR 201.100(c)(1), 201.128, 202.1(e)(6)(i)).

The materials misleadingly imply Focalin XR can mitigate consequences of untreated ADHD (e.g., low self-esteem, academic limitations, substance abuse, legal problems, impaired relationships, motor vehicle accidents, occupational difficulties) and achieve desired treatment outcomes (e.g., paying bills, avoiding speeding, decreased substance use). The FDA states that while Focalin XR improves ADHD symptoms, there's no substantial evidence it affects these broader outcomes.

Furthermore, the materials misleadingly claim long-term effectiveness and symptom control for Focalin XR, despite the FDA-approved labeling stating that effectiveness for long-term use (more than 7 weeks

Company
Novartis Pharmaceuticals Corp
Inspection date
September 25, 2008
Product type
Drugs
Office
Center for Drug Evaluation and Research
Person
  • Robert Dean (Director)
View Company Profile

ID · 833842ad-01ac-4287-a6ef-25540819eaf2

Violation Codes5
21 U.S.C. 352(a)21 U.S.C. 352(n)21 CFR 201.100(c)(1)21 CFR 201.12821 CFR 202.1(e)(6)(i)

Full citation text and observation details available on the Dashboard.

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Novartis Pharmaceuticals Corp
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.